Seelos Therapeutics, Inc.: cashflow_financing
| Value | {"amount": 91684000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-06-30 |
| Status | current |
| Entity | Seelos Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T09:53:13.881238+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/67ede707-bbe5-43ba-9d92-e73a3ceadb0b
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001136261-21-000187 · Open the official SEC filing →Retrieved: 2026-08-19T09:53:13.881238+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001017491/cashflow-financing/2021-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/67ede707-bbe5-43ba-9d92-e73a3ceadb0b
History
- no predecessors — first report